Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in India

This research service aims to provide an update on the epidemiology of Hepatitis C, including the prevalence and incidence, Market Engineering measurements, and government initiatives. It also covers patient source, load, and forecasts, while also outlining the key treaters involved. Current diagnostic methods are presented, followed by treatment regimens, their cost, and upcoming product launches. Clinical trials highlighting research into new treatments are also provided, along with an analysis of the pipeline. Additionally, there is a competitive analysis which includes the market structure, major participants, and future trends. This service covers the Hepatitis C therapeutics market in India

This Frost & Sullivan research service titled Multi-client Study: Opportunities Assessment for Hepatitis C Therapeutics Market in India provides an overview of Hepatitis C market, government initiatives, patient load and classification, patient forecasts, treatment regimens, product launches, and challenges faced by physicians.

This analysis is available through our Pharmaceuticals & Biotechnology Growth Partnership Services program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth. For more information on this custom subscription service, please click here.

Market Overview

Better Understanding of Diagnosis Enables the Rollout of Novel Treatments Options in the Hepatitis C Therapeutics Market in India

Ongoing efforts to raise disease awareness in India have increased the number of diagnosed cases and expanded the base of patients available for treatment. The prevalence of Hepatitis C virus (HCV) infection was 1.2 percent of the population in 2009. It is expected to grow at a compound annual growth rate (CAGR) of 1.6 percent from 13,770,000 persons with HCV in 2009 to 15,420,000 persons in 2016. Increasing population and high prevalence of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) have contributed to growing prevalence in the country. Greater clarity of diagnosis has facilitated the introduction of new treatment options. "The diagnosed patient base is expected to expand in the future with the gradual build-up in awareness, the number of Hepatitis C carriers, and access to urban healthcare facilities due to the improving rural economy and road infrastructure connecting rural areas with the nearest urban locations," notes the analyst of this research service. "The number of diagnosed patients has been on the rise since 2006 following mandatory screening and increasing detection facility in urban areas."

Although screening has been enhanced, only 9 percent of diagnosed patients are placed under treatment. The high cost of therapy coupled with numerous side effects results in treatment not being extended to a larger patient pool. The often debilitating side effects, frequent dosing, and lackluster efficacy of current HCV treatments have resulted in lack of compliance and have spurred the exploration of more effective treatments. Therapy for chronic Hepatitis C is currently limited to pegylated interferon in combination with ribavirin. While this combination can effectively clear the infection in some patients, it has limited efficacy in patients with genotype 1, who comprise 20 percent of HCV patients in India. The side effects of this treatment include lowered blood platelet count, depression, and hemolytic anemia. The low success rate of interferon, along with side effects, results in patients either avoiding or withdrawing from treatment. The combination of these factors represent missed treatment opportunities and thus, market share.

Public and private campaigns have been launched in India to ramp up disease awareness. However, more concerted efforts are required. Greater information outreach will enable patients to understand the treatment processes better and be more receptive toward those. The role of the government is minimal in raising the awareness level of public about Hepatitis C. The key opinion leaders (KOLs) and physicians involved in the treatment of Hepatitis C have emphasized that the government should take a more proactive role in educating the public on the disease. "Companies on their part must offer treatment options that expedite efficiency, have fewer side effects, and are cost efficient," says the analyst. "They must ensure that patients are aware of their disease status and compliant to treatment." Encouraging patients to remain compliant and providing incentives to stay on HCV treatment will increase the likelihood of future compliance, especially for improved treatments. Refined versions of current HCV drugs, oral formulations of small molecule inhibitors, and the new drug class known as protease inhibitors are in the development pipeline and represent the future of HCV treatment. New treatment options must be launched to capture this growing market. SHOW LESS READ MORE >

- 1 | EXECUTIVE SUMMARY

- - Executive Summary and Overview
- - - 1. Executive Summary

- 2 | HEPATITIS C THERAPEUTICS MARKET

- - Market Overview
- - - 1. Introduction
- - - 2. Context for the Study
- - - 3. Research Scope and Segmentation
- - - 4. Methodology
- - - 5. Restraints

- 3 | INDIAN HEPATITIS C THERAPEUTICS MARKET

- - Market Overview
- - - 1. Prevalence of Hepatitis C
- - - 2. Incidence of Hepatitis C
- - - 3. Measurements
- - - 4. Government Initiatives

- - Hepatitis C: Patient Load Source and Forecasts
- - - 1. Patient Source and Quantification
- - - 2. Key Treaters and Patient Flow
- - - 3. Patient Forecasts

- - Diagnosis and Treatment
- - - 1. Diagnostic Tests and Monitoring
- - - 2. Treatment Regimens
- - - 3. Cost of Treatment

- - Product Launches
- - - 1. Product Launches - Details

- - Clinical Trials
- - - 1. Clinical Trials - Details

- - Pipeline Analysis
- - - 1. Pipeline Analysis Details

- - Competitive Analysis
- - - 1. Competitive Structure

- - Future Trends
- - - 1. Future Trends

- - Problems Faced by Physicians
- - - 1. Asymptomatic Nature of Hepatitis C
- - - 2. Low Awareness of Hepatitis C
- - - 3. Side Effects of Current Treatment
- - - 4. No Treatment Option for Relapsers and Non-responders

- 4 | APPENDIX

- - 1. Total Population and Assumptions used in Estimating Patient Forecasts

List of Figures

Chapter 3
- Hepatitis C Therapeutics Market: Prevalence of Hepatitis C (India), 2006-2016
- Hepatitis C Therapeutics Market: Incidence of Hepatitis C (India), 2006-2016 3-4
- Hepatitis C Therapeutics Market: Patient Classification of Current HCV Patients Based on Interferon Usage (India), 2009
- Hepatitis C Therapeutics Market: Categorization of Patients Previously Treated with Interferons (India), 2009
- Hepatitis C Therapeutics Market: Forecasts of Diagnosed Hepatitis C Patients (India), 2006-2016
- Hepatitis C Therapeutics Market: Market Drivers Ranked in Order of Impact (India), 2010-2016
- Hepatitis C Therapeutics Market: Market Restraints Ranked in Order of Impact (India), 2010-2016
- Hepatitis C Therapeutics Market: Forecasts of Treated Hepatitis C Patients (India), 2006-2016
- Hepatitis C Therapeutics Market: Circumstances that Prompt Physicians to Test Patients for HCV (India), 2009
- Hepatitis C Therapeutics Market: Key Diagnostic Tests Required Prior to Initiating Therapy for Infection with HCV (India), 2009
- Hepatitis C Therapeutics Market: Tests Used and Key Clinical Indicators that Confirm a Patient's Progression from Acute HCV to Chronic Disease (India), 2009
- Hepatitis C Therapeutics Market: Classification of HCV Patients Based on Genotype (India), 2009
- Hepatitis C Therapeutics Market: Classification of HCV Patients Based on Interferon Therapy (India), 2006-2016
- Hepatitis C Therapeutics Market: Percent of Usage of Pegasys and Pegintron (India), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Acute HCV Patients (India), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 1 Chronic HCV Patients (India), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 2 and 3 Chronic HCV Patients (India), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 1 Naïve HCV Patients (India), 2009
- Hepatitis C Therapeutics Market: Treatment Regimen for Genotype 2/3 Naïve HCV Patients (India), 2009
- Hepatitis C Therapeutics Market: Advantages and Drawbacks of Prescribed Drugs (India), 2009
- Hepatitis C Therapeutics Market: List of Clinical Trials Conducted by Phase, Patient Age, Stage, Drug, and Sponsor (India), 2009
- Hepatitis C Therapeutics Market: List of Interferons in Development (World), 2009
- Hepatitis C Therapeutics Market: List of Small Molecule Antivirals in Development (World), 2009
- Hepatitis C Therapeutics Market: List of Non-interferons in Development (World), 2009
- Hepatitis C Therapeutics Market: Competitive Structure (India), 2009
- Hepatitis C Therapeutics Market: Company Market Share by Physician's HCV Patient Load (India), 2009

Chapter 4
- Hepatitis C Therapeutics Market: Total Population and Population Growth Rate (India), 2006-2016